INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) said the DINAMO phase III clinical trial met its primary endpoint by showing a statistically significant reduction in HbA1c, a marker of average blood sugar, with Jardiance compared with placebo for children and adolescents aged 10-17 years living with type 2 diabetes. The overall safety data was generally consistent with previous findings in adults with type 2 diabetes. A secondary endpoint from the trial showed that at week 26, Jardiance reduced fasting plasma glucose.
The company said the findings have been submitted for publication in a peer-reviewed journal.
For More Such Health News, visit rttnews.com.
Copyright(c) 2022 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX